EUVIMEDEUVIMED entdecken
Crossref

The evolution of tyrosine‐kinase‐targeted cancer therapies

Mike Leahy

Future Prescriber · 2006

DOI: 10.1002/fps.14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Mike Leahy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.

Zitieren

APA

Leahy, M. (2006). The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. https://doi.org/10.1002/fps.14

Vancouver

Leahy M. The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. 2006. doi:10.1002/fps.14

BibTeX
@article{Leahy2006,
  author = {Leahy, Mike},
  title = {The evolution of tyrosine‐kinase‐targeted cancer therapies},
  journal = {Future Prescriber},
  year = {2006},
  doi = {10.1002/fps.14}
}
Kostenlos starten →